- Home
- SUI vs EXEL Comparison
SUI vs EXEL Comparison
Compare SUI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SUI | EXEL |
|---|---|---|
| Founded | 1975 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 12.7B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SUI | EXEL |
|---|---|---|
| Price | $119.93 | $65.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 19 | 18 |
| Target Price | ★ $136.84 | $54.87 |
| AVG Volume (30 Days) | 1.0M | ★ 2.0M |
| Earning Date | 10-26-2026 | 10-29-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | ★ 1426.76 | 57.95 |
| EPS | N/A | ★ 1.60 |
| Revenue | ★ $2,306,100,000.00 | $452,477,000.00 |
| Revenue This Year | N/A | $10.09 |
| Revenue Next Year | $2.06 | $13.62 |
| P/E Ratio | ★ N/A | $40.46 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $109.77 | $36.00 |
| 52 Week High | $137.85 | $64.78 |
Technical Indicators
Market Signals| Indicator | SUI | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 76.42 |
| Support Level | $117.28 | $54.38 |
| Resistance Level | $125.03 | N/A |
| Average True Range (ATR) | 2.15 | 1.61 |
| MACD | 0.98 | 0.52 |
| Stochastic Oscillator | 94.90 | 97.11 |
Price Performance
Historical ComparisonAbout SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and recreational vehicle communities. The company currently owns a portfolio of 455 properties, which includes 295 manufactured housing communities and 160 RV communities. Sun targets owning properties that are desirable as second homes or vacation properties, with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.